01—Abstract
Summary
Summary of the 8-K filed May 11, 2026. Cited figures are marked; the original filing is the authoritative source.
Byrn, Inc. (BRRN) has undergone a significant change in control and leadership.
MEDO Healthcare LLC has acquired a controlling stake of approximately 84.7% of the company's voting power through the purchase of 10 million shares of Series A-1 Preferred Stock for $175,000a. This transaction, which occurred on April 24, 2026, has resulted in a substantial shift in beneficial ownership, with Jean Christophe Chopin now holding 63.1% of the common stock, but MEDO Healthcare LLC wielding dominant voting power due to the preferred stock. Concurrently, David Lazar has resigned as the sole director and officer.
John Leo has been appointed as the new Chief Executive Officer and sole director, and Arthur Magee has been appointed as CFO and Secretary. Both Leo and Magee bring extensive experience in investment banking and corporate finance from Primary Capital LLC, suggesting a strategic focus on financial operations and potential growth initiatives.
02—Key points
Key Highlights
- MEDO Healthcare LLC acquired a controlling voting interest (84.7%) in Byrn, Inc. by purchasing 10 million shares of Series A-1 Preferred Stock.
- The acquisition of voting control by MEDO Healthcare LLC was for a cash consideration of $175,000.
- David Lazar, the former sole director and officer, has resigned from his positions.
- John Leo has been appointed as the new Chief Executive Officer and sole director of the company.
- Arthur Magee has been appointed as the Chief Financial Officer and Secretary.
- The new management team, John Leo and Arthur Magee, possess significant experience in investment banking and corporate finance, particularly through their roles at Primary Capital LLC.
- Jean Christophe Chopin remains a significant shareholder, holding 63.1% of the common stock outstanding.
03—Questions
Frequently Asked Questions
What was the nature of the change in control at Byrn, Inc.?
The change in control was triggered by MEDO Healthcare LLC's acquisition of 10 million shares of Series A-1 Preferred Stock from Custodian Ventures LLC (David Lazar's holding company) for $175,000. This purchase granted MEDO Healthcare LLC approximately 84.7% of the total voting power of Byrn, Inc., effectively transferring control.
Who are the new key management personnel and what is their background?
John Leo has been appointed as the new CEO and sole director, bringing over 30 years of financial services experience, including extensive M&A and capital markets expertise, and experience as CEO of FINRA member firms and bank holding companies. Arthur Magee is the new CFO and Secretary, with a strong background in investment banking, corporate finance, and raising capital for emerging growth companies, including over 15 years at global banks and boutique firms.
What is the voting structure of Byrn, Inc. after this transaction?
Following the transaction, MEDO Healthcare LLC holds the dominant voting power at 84.7% through its Series A-1 Preferred Stock. Each share of this preferred stock carries voting rights equivalent to 250 common shares. Jean Christophe Chopin holds a significant stake in common stock (63.1%), but his voting power is diluted by the preferred stock's influence. The newly appointed CEO, John Leo, also has a notable ownership stake through his interest in MEDO Healthcare LLC.
What are the implications of this change for the company's strategic direction?
The appointment of John Leo and Arthur Magee, both with deep expertise in investment banking, corporate advisory, and capital raising, suggests a potential strategic shift towards financial restructuring, mergers and acquisitions, or growth financing. Their track record with emerging growth companies and complex financial transactions indicates a focus on enhancing shareholder value and potentially positioning the company for future opportunities.
04—Continue